May 1 (Reuters) – Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker’s shares up over 55% in premarket trading.
Under the terms of the agreement, Esperion shareholders will receive $3.16 in cash for each share, representing a premium of about 58% to the company’s last closing price.
Shareholders could also receive additional contingent payments totaling up to $100 million if Esperion meets certain sales targets in the coming years, the companies said.
As of last close, Esperion had a market value of $514.81 million, according to data compiled by LSEG.
The deal is expected to close in the third quarter of 2026.
(Reporting by Sriparna Roy and Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
